Contrast Enhanced Ultrasound to Evaluate Response to Chemoembolization in Patients With Liver Tumors (NCT06261814)
2D and 3D Contrast Enhanced Ultrasound of Chemoembolization
🩺 Plain-English Summary (8th-Grade Level)
This phase II trial evaluates the diagnostic performance of contrast-enhanced ultrasound (CEUS) for assessing treatment response in patients undergoing transarterial chemoembolization (TACE) for liver tumors. TACE is a hepatic artery embolization technique involving the injection of a blocking agent and a chemotherapy agent to treat liver cancers. Currently, contrast enhanced magnetic resonance imaging or computed tomography are used to assess disease response 1-2 months after TACE treatment, but ultrasound may be a less expensive, earlier alternative. CEUS is an imaging procedure that uses high-frequency sound waves to generate images of the body after administering Lumason, an imaging agent used to enhance visualization of blood flow on ultrasounds. CEUS is able to be performed during the TACE procedure, making it possible to evaluate treatment response earlier than standard techniques. CEUS may be an effective method to evaluate treatment response more accurately and much earlier than current standard evaluation methods.
Who can join: Review the eligibility criteria below.
Location: Sidney Kimmel Cancer Center at Thomas Jefferson University — Philadelphia, Pennsylvania
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Sidney Kimmel Cancer Center at Thomas Jefferson University — Philadelphia, Pennsylvania
📞 Contact the Study Coordinator
Phone: (215) 503-5188
Email: john.eisenbrey@jefferson.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Liver Neoplasms
- The HistoSonics System for Treatment of Primary and Metastatic Liver Tumors Using Histotripsy — Miami, Florida
- Hypovolemic Phlebotomy to Reduce Blood Transfusions in Major Hepatic Resections — Vancouver, British Columbia
- Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study) — Fullerton, California
Explore by condition: All Liver Neoplasms clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.